- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06820463
Une étude pour évaluer les événements indésirables et l'efficacité de l'intraveineux (IV) du télélisotuzumab adizutecan en combinaison avec l'oxaliplatine IV, le fluorouracile, l'acide folinique / leucovorine, le bevacizumab, le panitumumab chez les participants adultes atteints de cancer du cancer colorectal métastatique, le cancer du cancer métastatique colorectal, le panitumumab chez les participants adultes atteints de métastatique colorectal, le cancer du cancer colorectal métastatique, le panitumumab chez les participants adultes atteints de cancer du cancer colorectal métastatique, le cancer du cancer colorectal métastatique, le panitumumab chez les participants adultes atteints de métastatique colorectal colorectal (AndroMETa-CRC)
Une étude de protocole maître de phase 2, ouverte, randomisée et maître pour évaluer la sécurité et l'efficacité de plusieurs combinaisons de traitement avec le télélisotuzumab adizutecan chez les sujets atteints de cancer colorectal métastatique
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2109
- Recrutement
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, Australie, 4101
- Recrutement
- Mater Misericordiae /ID# 270694
-
Contact:
- Site Coordinator
- Numéro de téléphone: +61731632341
-
-
South Australia
-
Woodville South, South Australia, Australie, 5011
- Recrutement
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, Australie, 3084
- Recrutement
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 6009
- Recrutement
- One Clinical Research /ID# 270695
-
-
-
-
-
São Paulo, Brésil, 04014-002
- Recrutement
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, Brésil, 01401-002
- Recrutement
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 41253-190
- Recrutement
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brésil, 98700-000
- Recrutement
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, Brésil, 14784-400
- Recrutement
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, Brésil, 15090-000
- Recrutement
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Recrutement
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, Canada, T6G 1Z2
- Recrutement
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Recrutement
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, Canada, M5G 2M9
- Recrutement
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Recrutement
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, Espagne, 28027
- Recrutement
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, Espagne, 28046
- Recrutement
- Hospital Universitario La Paz /ID# 269730
-
Valencia, Espagne, 46010
- Recrutement
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, Espagne, 39008
- Recrutement
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, Espagne, 31008
- Recrutement
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
-
Paris, France, 75015
- Recrutement
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, France, 59037
- Recrutement
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, France, 86021
- Recrutement
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, France, 44000
- Recrutement
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, France, 75013
- Recrutement
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
-
Thessaloniki, Grèce, 54639
- Recrutement
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, Grèce, 12462
- Recrutement
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, Grèce, 14564
- Recrutement
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, Grèce, 18547
- Recrutement
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, Grèce, 55236
- Recrutement
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, Israël, 9103102
- Recrutement
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, Israël, 91120
- Recrutement
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, Israël, 4941492
- Recrutement
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israël, 6423906
- Recrutement
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, Italie, 20162
- Recrutement
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
Contact:
- Site Coordinator
- E-mail: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, Italie, 80138
- Recrutement
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 464-8681
- Recrutement
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japon, 216-8511
- Recrutement
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, Japon, 980-8574
- Recrutement
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Salzburg, L'Autriche, 5020
- Recrutement
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, L'Autriche, 1090
- Recrutement
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, L'Autriche, 8010
- Recrutement
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Recrutement
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, Porto Rico, 00917-5022
- Recrutement
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Manchester, Royaume-Uni, M20 4BX
- Recrutement
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, Royaume-Uni, E1 2ES
- Recrutement
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, Royaume-Uni, OX3 9DU
- Recrutement
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, Royaume-Uni, SM2 5PT
- Recrutement
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, Royaume-Uni, B9 5SS
- Recrutement
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
-
Kaohsiung City, Taïwan, 807
- Recrutement
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, Taïwan, 833
- Recrutement
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, Taïwan, 704
- Recrutement
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, Taïwan, 112
- Recrutement
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, Taïwan, 100
- Recrutement
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, Taïwan, 333
- Recrutement
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
-
-
-
Brno, Tchéquie, 656 53
- Recrutement
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, Tchéquie, 500 05
- Recrutement
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, Tchéquie, 128 00
- Recrutement
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, Tchéquie, 150 06
- Recrutement
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, Tchéquie, 140 59
- Recrutement
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Recrutement
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, États-Unis, 32803
- Recrutement
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, États-Unis, 30060
- Recrutement
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, États-Unis, 60521
- Recrutement
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109-5000
- Recrutement
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64111
- Recrutement
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130
- Recrutement
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- Recrutement
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45245
- Recrutement
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- Recrutement
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, États-Unis, 77598
- Recrutement
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- University Of Washington /ID# 271298
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Expérimental: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Expérimental: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Expérimental: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Expérimental: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Expérimental: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Expérimental: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Expérimental: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Délai: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
Délai: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Délai: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
Délai: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
Délai: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
Délai: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs colorectales
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Enzymes et coenzymes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Complexes de coordination
- Pyrimidines
- Formyltétrahydrofolate
- Tétrahydrofolat
- Acide folique
- Pterines
- Ptéridines
- Uracile
- Pyrimidinones
- Coenzymes
- Oxaliplatine
- Bévacizumab
- Panitumumab
- Fluorouracile
- Leucovorine
Autres numéros d'identification d'étude
- M24-533
- EU CT (Autre identifiant: 2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Délai de partage IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Critères d'accès au partage IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .